JPS58501130A - ヘムの代謝速度の低下方法 - Google Patents

ヘムの代謝速度の低下方法

Info

Publication number: JPS58501130A
Authority: JP; Japan
Prior art keywords: protoporphyrin; tin; heme; bilirubin; chromium
Prior art date: 1981-07-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP57502582A

Other languages

English (en)

Japanese (ja)

Other versions

JPH0411525B2 (pt

Inventor

カパス・アタラ−

ドラモンド・ジヨ−ジ

Original Assignee

ザ　ロツクフエラ−　ユニバ−シテイ

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-07-15

Filing date

1982-07-15

Publication date

1983-07-14

1982-07-15 Application filed by ザ　ロツクフエラ−　ユニバ−シテイ filed Critical ザ　ロツクフエラ−　ユニバ−シテイ

1982-07-15 Priority claimed from PCT/US1982/000955 external-priority patent/WO1983000287A1/en

1983-07-14 Publication of JPS58501130A publication Critical patent/JPS58501130A/ja

1992-02-28 Publication of JPH0411525B2 publication Critical patent/JPH0411525B2/ja

Status Granted legal-status Critical Current

Links

150000003278 haem Chemical class 0.000 title claims description 28
230000004060 metabolic process Effects 0.000 title claims description 9
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims description 58
238000000034 method Methods 0.000 claims description 27
229950003776 protoporphyrin Drugs 0.000 claims description 25
241000124008 Mammalia Species 0.000 claims description 13
239000000203 mixture Substances 0.000 claims description 10
KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 claims description 6
238000011282 treatment Methods 0.000 claims description 5
239000007864 aqueous solution Substances 0.000 claims description 3
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 2
238000009825 accumulation Methods 0.000 claims 2
239000008194 pharmaceutical composition Substances 0.000 claims 2
230000000694 effects Effects 0.000 description 13
102000016761 Haem oxygenases Human genes 0.000 description 9
108050006318 Haem oxygenases Proteins 0.000 description 9
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
241000700159 Rattus Species 0.000 description 8
210000004369 blood Anatomy 0.000 description 8
239000008280 blood Substances 0.000 description 8
210000004185 liver Anatomy 0.000 description 8
150000004032 porphyrins Chemical class 0.000 description 6
239000000243 solution Substances 0.000 description 6
235000002639 sodium chloride Nutrition 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
229910052742 iron Inorganic materials 0.000 description 4
230000037323 metabolic rate Effects 0.000 description 4
229910052751 metal Inorganic materials 0.000 description 4
239000002184 metal Substances 0.000 description 4
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000008859 change Effects 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
238000013519 translation Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
230000037396 body weight Effects 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
229910052804 chromium Inorganic materials 0.000 description 2
239000011651 chromium Substances 0.000 description 2
238000012937 correction Methods 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
239000003814 drug Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000006911 enzymatic reaction Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
229910052697 platinum Inorganic materials 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
210000002345 respiratory system Anatomy 0.000 description 2
238000007142 ring opening reaction Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000006276 transfer reaction Methods 0.000 description 2
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
229940045145 uridine Drugs 0.000 description 2
GWZYPXHJIZCRAJ-UHFFFAOYSA-N Biliverdin Natural products CC1=C(C=C)C(=C/C2=NC(=Cc3[nH]c(C=C/4NC(=O)C(=C4C)C=C)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O GWZYPXHJIZCRAJ-UHFFFAOYSA-N 0.000 description 1
RCNSAJSGRJSBKK-NSQVQWHSSA-N Biliverdin IX Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C/C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1 RCNSAJSGRJSBKK-NSQVQWHSSA-N 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
206010008748 Chorea Diseases 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
206010011469 Crying Diseases 0.000 description 1
206010011878 Deafness Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010023138 Jaundice neonatal Diseases 0.000 description 1
201000006346 Neonatal Jaundice Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
238000008050 Total Bilirubin Reagent Methods 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
208000005980 beta thalassemia Diseases 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
208000022806 beta-thalassemia major Diseases 0.000 description 1
QBUVFDKTZJNUPP-UHFFFAOYSA-N biliverdin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(C=C3C(=C(C=C)C(=O)N3)C)=N2)CCC(O)=O)N1 QBUVFDKTZJNUPP-UHFFFAOYSA-N 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000006931 brain damage Effects 0.000 description 1
231100000874 brain damage Toxicity 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
206010008129 cerebral palsy Diseases 0.000 description 1
208000012601 choreatic disease Diseases 0.000 description 1
208000035623 congenital anemia Diseases 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000003292 glue Substances 0.000 description 1
230000010370 hearing loss Effects 0.000 description 1
231100000888 hearing loss Toxicity 0.000 description 1
208000016354 hearing loss disease Diseases 0.000 description 1
239000003350 kerosene Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
238000001126 phototherapy Methods 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
230000002028 premature Effects 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
235000011121 sodium hydroxide Nutrition 0.000 description 1
229910052712 strontium Inorganic materials 0.000 description 1
CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
238000011421 subcutaneous treatment Methods 0.000 description 1
239000013589 supplement Substances 0.000 description 1
150000003606 tin compounds Chemical class 0.000 description 1
231100000816 toxic dose Toxicity 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000004383 yellowing Methods 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Landscapes

Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP57502582A 1981-07-15 1982-07-15 ヘムの代謝速度の低下方法 Granted JPS58501130A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US285373FREGB		1981-07-15
PCT/US1982/000955 WO1983000287A1 (en)	1981-07-15	1982-07-15	Method of decreasing the rate of heme metabolism and composition used therefor

Publications (2)

Publication Number	Publication Date
JPS58501130A true JPS58501130A (ja)	1983-07-14
JPH0411525B2 JPH0411525B2 (pt)	1992-02-28

Family

ID=22168093

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP57502582A Granted JPS58501130A (ja)	1981-07-15	1982-07-15	ヘムの代謝速度の低下方法

Country Status (1)

Country	Link
JP (1)	JPS58501130A (pt)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7777028B2 (en)	2002-06-04	2010-08-17	Infacare Pharmaceutical Corporation	Preparation of metal mesoporphyrin compounds
US7960371B2 (en)	2006-10-04	2011-06-14	Infacare Pharmaceutical Corporation	High-purity large-scale preparation of stannsoporfin
US8735574B2 (en)	2011-03-30	2014-05-27	Infacare Pharmaceutical Corporation	Methods for synthesizing metal mesoporphyrins

1982
- 1982-07-15 JP JP57502582A patent/JPS58501130A/ja active Granted

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8178664B2 (en)	2002-06-04	2012-05-15	Infacare Pharmaceutical Corporation	Preparation of metal mesoporphyrin compounds
US7777028B2 (en)	2002-06-04	2010-08-17	Infacare Pharmaceutical Corporation	Preparation of metal mesoporphyrin compounds
US9107927B2 (en)	2006-10-04	2015-08-18	Infacare Pharmaceutical Corporation	High-purity large-scale preparation of stannsoporfin
US8530458B2 (en)	2006-10-04	2013-09-10	Infacare Pharmaceutical Corporation	High-purity large-scale preparation of stannsoporfin
US8835416B2 (en)	2006-10-04	2014-09-16	Infacare Pharmaceutical Corporation	High-purity large-scale preparation of stannsoporfin
US7960371B2 (en)	2006-10-04	2011-06-14	Infacare Pharmaceutical Corporation	High-purity large-scale preparation of stannsoporfin
US9517239B2 (en)	2006-10-04	2016-12-13	Infacare Pharmaceutical Corporation	High-purity large-scale preparation of stannsoporfin
US9902745B2 (en)	2006-10-04	2018-02-27	Infacare Pharmaceutical Corporation	High-purity large-scale preparation of stannsoporfin
US10273255B2 (en)	2006-10-04	2019-04-30	Infacare Pharmaceutical Corporation	High-purity large-scale preparation of stannsoporfin
US10662209B2 (en)	2006-10-04	2020-05-26	Mallinckrodt Hospital Products IP Limited	High-purity large-scale preparation of stannsoporfin
US11078220B2 (en)	2006-10-04	2021-08-03	Mallinckrodt Hospital Products IP Limited	High-purity large-scale preparation of stannsoporfin
US8735574B2 (en)	2011-03-30	2014-05-27	Infacare Pharmaceutical Corporation	Methods for synthesizing metal mesoporphyrins
US9181285B2 (en)	2011-03-30	2015-11-10	Infacare Pharmaceutical Corporation	Methods for synthesizing metal mesoporphyrins
US9688705B2 (en)	2011-03-30	2017-06-27	Infacare Pharmaceutical Corporation	Methods for synthesizing metal mesoporphyrins
US10533024B2 (en)	2011-03-30	2020-01-14	Mallinckrodt Hosptial Products Ip Limited	Methods for synthesizing metal mesoporphyrins

Also Published As

Publication number	Publication date
JPH0411525B2 (pt)	1992-02-28

Publication	Publication Date	Title
DE602004008927T2 (de)	2008-06-05	Verwendung von nitritsalzen zur behandlung von kardiovaskulären erkrankungen
Haeger-Aronsen et al.	1976	Antagonistic effect in vivo of zinc on inhibition of δ-aminolevulinic acid dehydratase by lead
Lucis	1983	The status of metformin in Canada
Goldman et al.	1970	Use of dithiothreitol to correct cystine storage in cultured cystinotic fibroblasts
Bishop et al.	1998	Pyrroloquinoline quinone: a novel vitamin?
Paller et al.	1997	Purpuric phototherapy-induced eruption in transfused neonates: relation to transient porphyrinemia
US4699903A (en)	1987-10-13	Therapeutic use of tin diiododeuteroporphyrin
US4684637A (en)	1987-08-04	Method of decreasing rate of heme metabolism
Cunningham	1956	Resorcin poisoning
JP2868525B2 (ja)	1999-03-10	新生児黄疸の予防方法
EP0084053B1 (en)	1987-09-09	Pharmaceutical composition and the use of sn- or cr-protoporphyrin for the manufacture thereof
US5162313A (en)	1992-11-10	Control of heme and iron concentrations in body tissues
JPS58501130A (ja)	1983-07-14	ヘムの代謝速度の低下方法
AU595047B2 (en)	1990-03-22	Therapeutic use of tin diiododeuteroporphyrin
Laliberte et al.	1976	The influence of fasting and stress on the response of rats to warfarin.
EP0199888B1 (en)	1992-06-24	Control of heme and iron concentrations in body tissues
RU2189813C1 (ru)	2002-09-27	Лекарственное средство антигипоксического действия
JP3035343B2 (ja)	2000-04-24	腸内鉄吸収性を制御するための経口投与ポルフィリン類
Lindeman et al.	2025	Runaway uncoupling in 2, 4-dinitrophenol poisoning: Clinical and mitochondrial observations from two cases
RU2149013C1 (ru)	2000-05-20	Биостимулирующее средство и способ лечения соматических заболеваний
RU2098102C1 (ru)	1997-12-10	Лекарственное средство для лечения железодефицитных анемий у детей
GORCHAKOVA et al.	2022	Igor BELENICHEV
RU2776671C2 (ru)	2022-07-22	Применение клатратного комплекса 20-гидроксиэкдизона с арабиногалактаном для нормализации обмена веществ, повышения неспецифической резистентности, роста и развития животных
Yeung et al.	2024	Sodium nitrite-induced methemoglobinaemia: a case report
Gollan et al.	1985	Bilirubin metabolism and congenital jaundice